Abstract
Lamivudine is a nucleoside reverse transcriptase inhibitor that is widely used for the treatment of HIV-1 infection in combination with other antiretrovirals. It is a highly effective agent that can be dosed once or twice daily due to its long intracellular half-life. It also has one of the best tolerability and long-term safety profiles among all antiretroviral agents and continues to be preferred as part of initial or subsequent combination therapy in HIV-infected patients.
MeSH terms
-
Animals
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / metabolism
-
Anti-HIV Agents / pharmacokinetics
-
Anti-HIV Agents / pharmacology
-
Anti-HIV Agents / therapeutic use*
-
Clinical Trials as Topic
-
Drug Utilization
-
HIV Infections / drug therapy*
-
HIV Infections / epidemiology
-
HIV Infections / virology
-
HIV-1
-
Humans
-
Lamivudine / adverse effects
-
Lamivudine / metabolism
-
Lamivudine / pharmacokinetics
-
Lamivudine / pharmacology
-
Lamivudine / therapeutic use*
-
Legislation, Drug
-
Reverse Transcriptase Inhibitors / adverse effects
-
Reverse Transcriptase Inhibitors / metabolism
-
Reverse Transcriptase Inhibitors / pharmacokinetics
-
Reverse Transcriptase Inhibitors / therapeutic use*
Substances
-
Anti-HIV Agents
-
Reverse Transcriptase Inhibitors
-
Lamivudine